On this page

Torphadine®

Butorphanol Tartrate

Veterinary ANADA Approved 3,281 adverse event reports

Overview

Source: Animal Drugs @ FDA
Proprietary name
Torphadine®
Active ingredient
Butorphanol Tartrate
Application type
ANADA
Sponsor
Dechra Veterinary Products LLC
Applications on record
1
First published
October 7, 2022

Adverse event reports

Source: openFDA VeDDRA
3,281
Reports mentioning this ingredient
May 26, 1987 – March 24, 2026
975
Classified serious
per reporter assessment
371
Lack of expected efficacy
resistance signal
13
Human operator exposure
needle-stick or splash
Not a risk measure. Veterinary adverse event reports are influenced by how many animals are treated, reporting practice and product age. Reports do not establish that the product caused the event, and a single report can cover an entire herd or flock. Attribution here is by active ingredient because the source dataset redacts brand names.

Attributed by active ingredient “BUTORPHANOL TARTRATE”. Green Book ingredient names and VeDDRA ingredient names do not always agree exactly, so attribution is approximate and labelled as such.

Reported reactions

Source: openFDA VeDDRA

Clinical signs coded in the VICH VeDDRA four-level hierarchy, most frequent first.

Reaction terms reported for this ingredient, by report count.
Reaction (VeDDRA term) Reports Relative frequency
Death 321
Tablets, Abnormal 158
Vomiting 155
Cardiac arrest 141
Anorexia 120
Fever 109
Ataxia 106
Depression 104
Bradycardia 96
Death by euthanasia 94
Apnoea 92
Lack of efficacy - NOS 88
INEFFECTIVE, SEDATION 87
Recovery prolonged 87
Diarrhoea 81
Convulsion 76
Sedation prolonged 76
Tachycardia 69
Elevated alanine aminotransferase (ALT) 65
Vocalisation 61

Species affected

Source: openFDA VeDDRA
Dog 1,689 Cat 849 Horse 172 Other 24 Human 11 Rabbit 5 Cattle 4 Guinea Pig 4 Alpaca 3 Donkey 3 Sheep 2 Chicken 2

Regulatory context

Abbreviated New Animal Drug Application (ANADA). A generic animal drug demonstrating bioequivalence, pharmaceutical equivalence and identical manufacturing criteria to the pioneer application. Veterinary generics have no formal therapeutic-equivalence coding system; they match the pioneer NADA specification instead.

Extra-label use in food-producing animals is governed by the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) and 21 CFR Part 530. It requires a valid veterinarian-client-patient relationship and is prohibited outright for certain drug classes. Withdrawal times are determined by FARAD, not by this index.

Sources for this page

Animal Drugs @ FDA FDA CVM Applications, sponsor, status, withdrawal
Animal & Veterinary Events FDA CVM VeDDRA adverse event aggregates by active ingredient